Aandelen in “Gezondheidstechnologie”

Aandeel Datum Koers Evolutie
vlag Y-Mabs Therapeutics Inc 17:21 11,920 USD
-7,38% 		-7,38%
vlag Yourgene Health Plc 7/09 0,515 GBX
0,00% 		0,00%

Nieuws over “Gezondheidstechnologie”

14:30 · Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences · Persbericht

14:30 · Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences · Persbericht

14:26 · iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates · Persbericht

14:24 · iTeos Therapeutics Announces $120 Million Registered Direct Offering · Persbericht

14:05 · Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

14:01 · Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma · Persbericht

14:00 · Curis to Present Updated Data from the TakeAim Leukemia Study · Persbericht

13:30 · Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results · Persbericht

13:15 · Euronext Brussel: het tapijt van Belysse begint te vliegen · Tijd.be (€)

De rentehooprally houdt aan en stuurt de Europese beurzen naar een nieuwe piek. Belysse begint zijn schuldenprobleem onder controle te krijgen en dat valt zeer in de smaak. Argenx kan wat herstellen n...

13:05 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

08:15 · Novavax Reports First Quarter 2024 Financial Results and Operational Highlights · Persbericht

08:00 · Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines · Persbericht

08:00 · Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines · Persbericht

08:00 · Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines · Persbericht

07:00 · Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 12, 2024 · Persbericht

06:36 · Beursrally wint vaart | Argenx beperkt schade op Nasdaq · Tijd.be (€)

In contrast met de manisch-depressieve handel op Euronext beperkte Argenx tijdens de - veel drukkere - handel op Nasdaq donderdagavond de schade.

9/05 · DBV Technologies to Participate in Upcoming Investor Conferences · Persbericht

9/05 · Nektar Therapeutics Reports First Quarter 2024 Financial Results · Persbericht

9/05 · Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer · Persbericht

9/05 · Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates · Persbericht

9/05 · PacBio Announces First Quarter 2024 Financial Results · Persbericht

Mijn selecties